|
| | Website | www.amgen.com | | Year Founded | 1980 | | President | Kevin W. Sharer | | CEO | Kevin W. Sharer | | CFO | Robert Bradway | | Chief Medical Officer | Sean Harper | | Marketing Contact | Craig Brooks | | Research Contact | Roger Perlmutter, M.D., Ph.D. | | Legal Affairs Contact | David J. Scott | | Ownership | Public Corporation | | Year of IPO | 1983 | | Stock Symbol | Nasdaq:AMGN | | Number of Employees | ~10,000 | | Business Focus | Amgen is a leading human therapeutics company in the biotechnology industry. For more than 25 years, the company has tapped the power of scientific discovery and innovation to advance the practice of medicine and dramatically improve the quality of people's lives.
Amgen pioneered the development of novel products based on advances in recombinant DNA and molecular biology and launched the biotechnology industry’s first blockbuster medicines. Today, as a Fortune 500 company serving millions of patients, Amgen continues to be an entrepreneurial, science-driven enterprise dedicated to helping people fight serious illness.
| | Primary Business | Research & Development, Manufacturer/Developer (diagnostics; instruments; consumables; and computer tools) | | Technologies Used In-House | Antibody Technology, Assays & High-Throughput Screening, Biomarkers, Cell/Tissue Culture, Genomics, Mass Spectrometry, Microarrays, Metabolomics, Proteomics, RNA | | Research Collaborations | 2007 - Oxford Genome Sciences (UK) Ltd " entered into a strategic collaboration with Amgen to discover, develop and
commercialise novel therapeutic antibodies for the treatment of cancer. The companies will generate fully human antibodies using Amgen's XenoMouse(R) technology, which was acquired through its acquisition of Abgenix. These antibodies will be raised against the novel druggable targets that OGeS has identified through its unique Oxford Genome Anatomy Project (OGAP(R)) database.
2006-Alcon, Inc. and Amgen signed a collaboration to jointly research, develop, and commercialize therapeutics for the treatment of eye diseases. The agreement encompasses multiple biological targets and disease areas within the field of ophthalmology.
2006-Galapagos' services division, BioFocus extended its drug discovery collaboration with Amgen for biology, computational/medicinal chemisrty services, and supply of biologically directed library compounds for Amgen's ion channel lead discovery programs, throughout 2006.
| | Licensing Agreements | 2007 - InteKrin Therapeutics, Inc. entered into a license agreement with Amgen Inc. under which InteKrin has obtained worldwide development and commercialization rights to Amgen's PPAR gamma selective modulator and partial agonist, INT131. Formerly known as AMG131 and first developed by Tularik, Inc., this compound utilizes a well-validated and potent target for the treatment of diabetes and insulin resistance.
2006-Biovitrum and Amgen have expanded their licensing deal to develop Biovitrum's small molecule 11beta-HSD1 enzyme inhibitors for the treatment of metabolic diseases.
2006-Human Genome Sciences signed a license agreement with Amgen under which Amgen aquired exclusive, worldwide rights to develop and commercialize therapeutic biological products for human use, based on a human gene that was discovered by Human Genome Sciences that may have potential applications in autoimmune diseases, immune deficiencies or suppression of cancer.
2006-Amgen and Genentech Inc. entered into license agreements granting licenses to each other under multiple patents relating to the manufacture and use of antibodies and related technology. These agreements include a grant by Genentech to Amgen of a license for multiple antibodies under the Cabilly patent family (U.S. Patent No. 6,331,415 et al.) relating in part to methods of producing immunoglobulins.
| | Markets firm is involved in | Biologics, Pharmaceuticals | | Major Products on Market | EPOGEN (epoetin alfa) For the treatment of anemia associated with chronic renal failure in dialysis patients
NEUPOGEN (filgrastim) For the prevention of infection in cancer patients undergoing certain types of chemotherapy
ARANESP (darbepoetin alfa) For the treatment of chemotherapy-induced anemia in patients with nonmyeloid malignancies and for anemia associated with renal failure
NEULASTA (pegfilgrastim) For the prevention of infection in cancer patients undergoing certain types of chemotherapy
KINERET (anakinra) For the treatment of signs and symptoms of rheumatoid arthritis
ENBREL (etanercept) For the treatment of rheumatoid and psoriatic arthritis
| | Research and/or Biotechnology Products Under Development | AMG 102 Cancer Oncology Phase 1
AMG 108 Rheumatoid arthritis Inflammation Phase 2
AMG 221 Type 2 diabetes Metabolic Disorders Phase 1
AMG 317 Asthma Inflammation Phase 1
AMG 379 Pain Neuroscience Phase 1
AMG 386 Cancer Oncology Phase 1
AMG 403 Pain Neuroscience Phase 1
AMG 479 Cancer Oncology Phase 1
AMG 531 Immune thrombocytopenic purpura (an autoimmune bleeding disorder) (romiplostim) Oncology Phase 3
AMG 623 Systemic lupus erythematosus Inflammation Phase 1
AMG 655 Cancer Oncology Phase 1
AMG 706 Cancer Oncology Phase 2
AMG 714 Psoriasis Inflammation Phase 1
AMG 745 Cachexia Oncology Phase 1
Apo2L/TRAIL Cancer Oncology Phase 1
Aranesp® (darbepoetin alfa) Anemia of cancer in patients not receiving chemotherapy Oncology Phase 3
Aranesp® (darbepoetin alfa) Cardiovascular disease in patients with chronic kidney disease and type 2 diabetes General Medicine† Phase 3
Aranesp® (darbepoetin alfa) Anemia in heart failure General Medicine† Phase 3
Denosumab Bone loss induced by hormone ablation therapy for breast cancer or prostate cancer Oncology Phase 3
Denosumab Bone metastases (cancer spread to bone) in breast cancer Oncology Phase 3
Denosumab Postmenopausal osteoporosis Metabolic Disorders Phase 3
Denosumab Rheumatoid arthritis Inflammation Phase 2
Denosumab Bone metastases-free survival Oncology Phase 3
Kepivance® (palifermin) Oral mucositis associated with radiation therapy and chemotherapy for solid tumors
Nplate is an investigational thrombopoiesis-stimulating Fc-peptide fusion protein ("peptibody") that contains two component regions
Oncology Phase 3
Sclerostin Ab Bone loss Metabolic Disorders Preclinical
Sensipar® (cinacalcet HCI) Primary hyperparathyroidism Metabolic Disorders Phase 2
Sensipar® (cinacalcet HCI) Secondary hyperparathyroidism in chronic renal insufficiency Metabolic Disorders Phase 3
Sensipar® (cinacalcet HCI) Cardiovascular disease in patients with secondary hyperparathyroidism and chronic kidney disease undergoing maintenance dialysis Metabolic Disorders Phase 3
Vectibix™ (panitumumab) First- and second-line colorectal cancer Oncology Phase 3
Vectibix™ (panitumumab) Head and neck cancer Oncology Phase 3 | | Subsidiaries and Affiliate Companies | Amgen has acquired Immunex, Kinetix, Synergen. |
|
